- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 12
The Center for Biosimilars® recaps the top stories for the week of August 12, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 12, 2019.
Number 5: Being presented with positively framed information on biosimilars is linked with greater willingness to accept a switch, says a recent study.
Number 4: New data from a phase 3 study in patients with rheumatoid arthritis show that Fresenius Kabi’s biosimilar adalimumab has similar safety to Humira.
Number 3: A retrospective analysis of prescription claims shows the importance of an oncology specialty pharmacy team in ensuring access to financial assistance.
Number 2: Authors of a new paper say it’s time to replace the totality of the evidence approach to biosimilars with a new paradigm.
Number 1: A judge ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi.
Finally, last week, our e-newsletter asked whether you think that Celltrion’s proposed subcutaneous infliximab biosimilar could compete with brand-name adalimumab.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
